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ABSTRACT
The tissue-selective estrogen complex (TSEC)
has recently entered the market for the
treatment of postmenopausal osteoporosis,
and is particularly targeted to women with
significant vasomotor symptoms. This review
appraises the evidence behind the only
approved TSEC to-date, a combination of
bazedoxifene and conjugated estrogens, with
regards to its efficacy and relevant safety
concerns. The majority of evidence that has
led to its approval is derived from the SMART
study. This large phase III trial with several
substudies was aimed at discerning the effects of
the TSEC on various estrogen-responsive tissues
in comparison to raloxifene and placebo.
Overall, the evidence thus far suggests a
superior improvement in lumbar bone mineral
density of 1.01% ± 0.28% as well as decrease in
the frequency of hot flushes. Regarding safety
concerns, endometrial thickness did not change
over the treatment course, and investigators
also identified a modest reduction in breast
density. While there was no difference in rates
of venous thromboembolism between
treatment and placebo groups in a 2-year
follow-up period, the effects of the drug on
coagulation profiles are similar to those seen
with hormone replacement therapy. Thus, the
drug’s effects on venous thromboembolism risk
over a longer treatment course remain unclear.
In conclusion, the actual efficacy of the TSEC
for postmenopausal osteoporosis remains as yet
undefined, given the lack of fracture prevention
data. The evidence thus far does seem to suggest
a beneficial effect on vasomotor symptoms and
a generally favorable side effect profile.
However, it should be noted that only one
study has addressed this question thus far, and
so the repeatability of the findings is still in
question.
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OSTEOPOROSIS: THE BURDEN
OF ILLNESS
Osteoporosis is perhaps one of the most under-
recognized chronic diseases when considering
its prevalence and its associated morbidity and
mortality. In Canada, osteoporotic fractures are
more common than the combined incidence of
heart attacks, strokes, and breast cancer,
representing a very large disease burden [1, 2].
An estimated one-third of women and one-fifth
of men will incur an osteoporotic fracture in
their lifetime, and the disease represents 3.9
billion dollars in cost to the Canadian health
care system [1, 2]. The skeletal affliction is
highly prevalent internationally as well. In
Europe and the United States, there are 1.7
million and 0.3 million hip fractures per year,
respectively, with the overwhelming majority of
these representing osteoporotic fractures [2].
Not only are these fractures highly prevalent,
but patients who sustain hip or vertebral
fractures also have higher mortality rates [3].
OSTEOPOROSIS AND MENOPAUSE
The risk factors for osteoporosis are long and
varied, but postmenopausal women remain the
largest cohort of those affected [4]. Both genders
begin to lose bone with advancing age, but
estrogen deficiency leads to an accelerated rate
of bone loss in postmenopausal women.
Estrogen acts to promote osteoblast activity.
Additionally, it inhibits the maturation of
osteoclast precursors and induces osteoclast
apoptosis. Through these combined effects
estrogen plays a critical role in maintaining
bone integrity and normal bone turnover [5].
The postmenopausal state is characterized by a
relative deficiency of estrogen and therefore
results in accelerated bone loss. Given that
postmenopausal women are at greatest risk for
osteoporosis, this population has attracted




Screening for osteoporosis with a dual X-ray
absorptiometry scan to assess bone mineral
density (BMD) is recommended for
postmenopausal women with significant risk
factors, including age over 65 or low body mass
index, as well as women over 50 years of age
with a preexisting fragility fracture. Clinicians
may use the World Health Organization
fracture risk assessment tool (FRAX) or another
risk assessment framework, like the Canadian
Association of Radiologists and Osteoporosis
Canada (CAROC) tool to predict 10-year
fracture risk [6]. Current treatment regimens
for high-risk patients include both lifestyle
modifications and pharmacologic options (see
Fig. 1). A variety of medications are available,
differing in mechanism of action, effectiveness,
and side effect profile. These include
bisphosphonates, the mainstay of therapy,
selective estrogen receptor modulators
(SERMs), hormone replacement therapy (HRT),
and biologic therapy with RANKL inhibition,
according to the most recent Canadian clinical
practice guidelines [7, 8]. Bisphosphonates and
denosumab, a RANKL inhibitor, are the most
frequently prescribed first-line therapies.
Regarding guidelines for prevention, lifestyle
modifications, including adequate dietary
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calcium and vitamin D are routinely
recommended, but there is ongoing
controversy about whether pharmacologic
therapy is indicated in those at moderate risk
of fracture [4, 5]. Given the long-term side
effects and concerns over attenuation of
treatment effectiveness of available therapeutic
options, patients in the intermediate risk group
present a challenge. Additionally, there is a lack
of evidence to guide specialists on preventative
treatment. Current guidelines in Canada
suggest that pharmacologic agents may be
considered in agreeable patients in this
intermediate category [4, 6, 9].
THE ROLE OF HORMONE
REPLACEMENT THERAPY
HRT once played an integral role in the
prevention and treatment of postmenopausal
osteoporosis (PMO). Since the Women’s Health
Initiative (WHI) study, however, there has been
a significant shift in perspective [10]. The side
effect profile has greatly altered the risk–benefit
balance of HRT. Evidence has repeatedly
suggested an increased risk of stroke,
thromboembolic events, and especially breast
cancer with prolonged use of HRT. Additionally,
lower doses of HRT do not produce significant
gains in BMD. Accordingly, its use in the
management of osteoporosis has declined
precipitously.
TIBOLONE
Tibolone, a synthetic steroid, was introduced as
an option for the management of
perimenopausal vasomotor symptoms. Its exact
mechanism of action is unclear, but the drug is
theorized to elicit its effects by means of variable
Fig. 1 Osteoporosis treatment algorithm. CAROC
Canadian Association of Radiologists and Osteoporosis
Canada, FRAX fracture risk assessment tool, HRT
hormone replacement therapy, SERM selective estrogen
receptor modulators, TSEC tissue-selective estrogen
complex
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estrogenic, progestogenic and androgenic
activity. At low doses, tibolone has been shown
to reduce bone turnover, increase both spine and
hip BMD, and reduce spinal fracture risk [11].
A Cochrane review on tibolone’s activity for
postmenopausal symptoms suggests lower
efficacy compared with HRT in the treatment of
postmenopausal symptoms [12]. Safety concerns
with HRT were mirrored with tibolone as well,
particularly increased risk of stroke in women
over 60 years old and increased risk of breast




Selective estrogen receptor modulators (SERMs)
came about as a potential alternative to HRT
with a more desirable side effect profile,
achieved via the variable action of SERMs on
different estrogen receptor-expressing tissues.
SERMs differ in their tissue-specific effects. The
ideal activity would produce antagonism in the
breast and endometrium, mitigating the risk of
breast and endometrial cancer seen with HRT.
Conversely, they should act as estrogen receptor
agonists in the bone and cardiovascular
systems, thus maintaining the estrogenic effect
on bone health [4]. These differential properties
led to approval for the use of certain SERMs in
the treatment of PMO.
Raloxifene is the oldest SERM in use for the
treatment of PMO. Two large studies, the MORE
(http://ClinicalTrials.gov number, NCT00670319)
and RUTH (http://ClinicalTrials.gov number,
NCT00190593) trials, both showed a reduction
in vertebral fracture risk [13]. While there is
no primary evidence to support reduction in
nonvertebral fractures, a post hoc secondary
analysis suggested nonvertebral efficacy in
those with the greatest vertebral deformity [14].
The perimenopausal period may also pose a
challenge for its use, as evidence suggests
increased incidence of hot flashes among
women treated with raloxifene [12, 13].
Additionally, there was a reduced risk of breast
cancer in postmenopausal women with
osteoporosis treated with raloxifene [15]. In
terms of effects on the endometrium, the MORE
trial did reveal an increased incidence of en-
dometrial polyps with raloxifene use; however,
multiple studies suggest that this does not
translate to an increased the risk of endometrial
hyperplasia or malignancy [16, 17]. Finally, the
increased risk of venous thromboembolism
(VTE) compared to placebo is still a concern
[18].
Bazedoxifene (BZA) is a newer generation
SERM indicated in the treatment of PMO. A
large, long-term, multicenter trial showed BZA
to be effective in reducing vertebral fractures
[19]. While there was also an improvement in
both lumbar and total hip bone mineral
densities, the drug failed to produce a tangible
reduction in nonvertebral fractures [19]. The
effects of the drug were particularly significant
in women with higher fracture risk. In fact, a
subgroup analysis suggested possible benefit
even for nonvertebral fractures in this subset
of women [20]. Thus, BZA has established itself
as a viable alternative to raloxifene in the
treatment of PMO.
Additionally, a recent network meta-analysis
showed that BZA provides comparable risk
reduction to bisphosphonates for nonvertebral
fractures in women at higher risk of fracture
based on their FRAX score [21]. However, this
was an indirect comparison of the two
medications, and a randomized-controlled trial
directly comparing the two drugs is needed to
confirm these results.
Regarding the safety of BZA, studies suggest
that the drug is generally tolerable and safe,
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even with long-term use. As expected, BZA did
not increase the incidence of breast,
endometrial or ovarian cancers [22]. However,
as with other SERMs, the main adverse events
(AEs) include a higher incidence of VTEs.
Furthermore, while the drug is generally well-
tolerated in nonflushing postmenopausal
women [23], evidence suggests that BZA
significantly exacerbates vasomotor symptoms,
particularly in perimenopause [20]. This poses
an obvious challenge in terms of tolerability
and compliance in postmenopausal women
who are affected by hot flushes.
DEVELOPMENT OF THE TISSUE-
SELECTIVE ESTROGEN COMPLEX
The tissue-selective estrogen complex, or TSEC,
was created in recognition of the need for a drug
that can concurrently relieve vasomotor
symptoms and treat PMO, while avoiding the
negative impacts of HRT alone. The TSEC
blends conjugated estrogens (CE) with a SERM,
aiming to retain the beneficial effects of
estrogen, while the SERM component acts to
diminish its harmful effects on the breast and
endometrium [24]. The experimental goal was
to achieve a combination that worked
synergistically to preserve bone health.
Various SERM/CE combinations had been
explored in both in vivo and in vitro studies;
however, BZA showed superior competitive
inhibition of CE in breast and endometrial
tissues, as well as promising effectiveness and
safety profile during testing in monkeys [15, 17,
18, 25–27]. The combination of 20 mg BZA and
0.45 mg CE (Duavee; Pfizer, Mission, KS, USA)
is the sole approved drug in this class. It entered
the market in October 2013, following approval
by the Food and Drug Administration [28]. The
main evidence leading to its approval was
derived from the SMART (http://ClinicalTrials.
gov number, NCT00808132) trial, consisting
of five large phase III multicenter substudies
evaluating the effectiveness and safety profile of
BZA/CE. The following sections will expand on
the current evidence behind BZA/CE and its
differential effects on various estrogen-respon-
sive tissues.
Bone Health
The primary indication for the TSEC is
purported to be the prevention of PMO. As
such, the osteoporosis substudy of the SMART-1
trial focused specifically on bone health and
relevant endpoints [29]. This 2-year
international multicenter randomized double-
blind placebo and active-controlled phase III
trial involved a total of 2315 patients spread
across two substudies: the first evaluated
subjects who were [5 years post-menopause
while the second enrolled those 1–5 years
post-menopause. There were eight subgroups
in each substudy, involving six different
combined doses of BZA/CE as well as
raloxifene and placebo. Subjects required a
baseline BMD score between -1.0 and -2.5 as
well as one additional risk factor for
osteoporosis to meet inclusion criteria. The
trial’s primary endpoint was change in lumbar
spine BMD at 2 years, with change in total hip
BMD and measured serum bone turnover
markers (BTM) as secondary endpoints. The
investigators found a significant increase in
BMD versus placebo for all BZA/CE doses;
however, higher doses of CE provided a more
significant change, while increasing doses of
BZA tended to dampen the effect. For the
current approved dose, 20 mg BZA/0.45 mg
CE, there was an adjusted annual increase in
lumbar spine BMD of 1.01% ± 0.28%, which
was significantly greater than both placebo and
raloxifene, with responder rates remaining
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higher at 24 months versus raloxifene. In
reference to secondary endpoints, all doses of
BZA/CE produced improvement in total hip and
femoral neck BMD versus placebo; however,
there was no significant difference from
raloxifene for the approved formulation [29].
Of interest, the SMART-5 trial (N = 1843)
compared BZA/CE to combined estrogen–
progestin therapy and found that BMD
improvements were greater in the latter group
[30]. Finally, there was a decrease in BTM for the
relevant dose of BZA/CE when compared to
both placebo and raloxifene, suggesting
reduced osteoclast activity [29].
Menopausal Symptoms
Both the SMART-1 and SMART-2 trials assessed
the effect of BZA/CE on vasomotor symptoms
and analyzed other parameters, including
quality of life and sleep. The SMART-1 trial
enrolled 3397 subjects divided into the eight
previously mentioned subgroups, and showed a
significant reduction in both daily hot flash
frequency and severity that persisted into the
second year of therapy [31, 32]. While there
were no significant differences in frequency of
sexual activity between treatment and controls,
rates of dyspareunia were reduced among those
in treatment groups. Finally, all intervention
groups were noted to have improvements in
vaginal atrophy compared with both controls
[31].
These results were confirmed in the SMART-3
trial (N = 664), which focused on subjects with
vaginal and vulvar atrophy [33, 34]. The
SMART-2 trial (N = 332), although smaller and
shorter, revealed similar outcomes. Significant
reductions in hot flush frequency and severity
were evident by week 4 for both doses of BZA/
CE tested, and by week 12, there was a 74%
reduction in daily hot flashes for the approved
BZA/CE dose. Notably, responder rates were
quite high for achievement of 50% reduction in
hot flush frequency [35, 36]. Outcomes related
to sleep, assessed by the Medical Outcomes
Study (MOS) sleep scale, and quality of life,
assessed by the menopause-specific quality of
life (MENQOL) questionnaire, were also
favorable [37, 28, 38].
Endometrial Proliferation
The risk of endometrial cancer associated with
unopposed estrogen therapy is prohibitive to its
use, even in patients with significant vasomotor
symptoms. Thus, the effect of TSECs on
endometrial proliferation are of key interest
and likely to affect prescribing practice. The
SMART-1 trial sought to answer this question,
and found that incidence of endometrial
hyperplasia was \1% and that no significant
change in endometrial thickness was
appreciated from baseline compared to 2 years
with 20 mg BZA/0.45 mg CE. Notably, at least
20 mg BZA was required to prevent endometrial
hyperplasia [29, 30]. The SMART-5 trial, which
included comparison with combined estrogen–
progestin therapy, did not confirm these results
entirely. While rates of hyperplasia were still
measured to be \1%, there was a significant
increase from baseline thickness of 0.17 mm as
well as a significant increase in endometrial
polyps; however, atypia was absent in all
specimens, and there were no cases of
endometrial carcinoma. Furthermore, the rates
of all endometrial endpoints were similar
between BZA/CE and combined estrogen–
progestin therapy [30].
Investigators also observed rates of uterine
bleeding and amenorrhea, in consideration of
pertinent side effects of HRT that prompt
treatment termination. Amenorrhea rates
([93% by cycles 10–13) were similar between
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treatment and placebo groups over the 2-year
period [39]. This suggests that BZA/CE may have
better tolerability, which has implications for
patient compliance.
BREAST DENSITY CHANGES
Increased risk of breast cancer remains a chief
concern when considering HRT. The TSEC is
proposed to provide a protective effect in this
regard. Thus, an ancillary, retrospective study
gathered mammographic evidence of SMART-1
participants to determine breast density
changes after treatment with BZA/CE.
Investigators found similar baseline breast
densities among all treatment arms, and a
modest but significant decrease of less than
0.5% was identified at 24 months with 20 mg
BZA/0.45 mg CE [40]. This certainly supports
the conjecture that the TSEC not only mitigates
the risk of breast cancer, but may also
counteract it.
Cardiovascular Effects
The effects of HRT on the cardiovascular system
have yet to be clearly defined. While previous
studies have suggested a protective role, the
WHI study not only failed to confirm this
postulation, but also showed that the reverse
may be true. However, critics point out that a
great proportion of subjects were older and
more distantly postmenopausal, potentially
confounding results [41]. Recent studies have
shown that estrogens may actually produce
favorable changes in lipid profile, thereby
altering coronary disease risk factors [42].
SERMs, BZA included, are thought to exert
similar effects on lipid profiles [43].
In light of this ongoing controversy, both
the SMART-1 and SMART-5 trials sought to
evaluate the cardiovascular effects of BZA/CE.
The SMART-5 trial found that total cholesterol
and low-density lipoprotein (LDL) levels were
similarly decreased with both BZA/CE and HRT.
Conversely, high-density lipoprotein (HDL)
levels were increased in both groups.
Interestingly, while there was a significant
increase in triglyceride levels in the HRT
group, there was no significant difference in
BZA/CE at 12 months [21, 36]. The SMART-1
trial confirmed the effects of BZA/CE on total
cholesterol, LDL and HDL; however, in
contradiction of the SMART-5 trial, there was a
significant increase in triglyceride levels at the
2-year mark compared to placebo. Additionally,
there was no difference in the incidence of
cardiovascular events between treatment and
placebo groups at 2 years [31]. Overall, these
results tend to suggest advantageous effects on
the lipid profile with BZA/CE therapy.
Coagulation Profile
VTEs are recognized complications of HRT and
SERMs [44]. Previous trials have shown an
elevated incidence of VTEs with BZA use as
well [45]. The SMART trials essentially showed a
neutral effect on hemostatic mechanisms.
However, changes in coagulation profiles were
similar to HRT in the SMART-5 trial [46]. Thus,
it is difficult to predict the effect of BZA/CE on
VTE rates based solely on its effects on
coagulation markers. The SMART-1 trial
directly measured rates of VTEs and found no
difference between treatment arms and placebo
[31]. Still, it should not escape notice that the
SMART-1 trial was conducted over 2 years,
while a previous phase III trial on BZA alone
did show more frequent VTEs over 5 years of
therapy. While the results of the SMART-1 trial
suggest promising evidence that VTE risk may
not present a barrier to use of BZA/CE, further
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confirmatory evidence is needed before drawing
strong conclusions in either direction.
Side Effects and Adverse Events
Rates of AEs were similar between the study
drug and placebo, including no significant
differences in rates of ischemic stroke, VTE,
and coronary heart disease at study termination
[31]. Only six deaths occurred, and were
presumed to have no connection to the study
drug [28]. The causes of these deaths were
bronchoaspiration, intracerebral hemorrhage,
metastatic lung cancer, chronic obstructive
pulmonary disease, and two cases of accidental
death [31]. The most common AEs requiring
treatment included headache, infection, pain,
and arthralgia, and there was no difference in
their incidence between treatment groups and
placebo. Furthermore, in the majority of cases,
these AEs were thought to be unrelated to the
study drug [35]. Combined with the neutral
effect on endometrial tissue and potentially
protective breast density changes, these results
suggest that BZA/CE is a safe therapeutic option.
In terms of tolerability, breast pain, a common
side effect ofHRTassociatedwithdiscontinuation
of treatment, did not appear at a greater
frequency in treatment arms. As mentioned
earlier, uterine bleeding appeared with lower
frequency in the BZA/CE as opposed to HRT,
suggesting a better side effect profile [47, 48].
CONCLUSIONS: WHERE WILL
THE TSEC FIT IN CLINICAL
PRACTICE?
Regarding use of the drug in patients requiring
vasomotor symptom relief, the evidence so far is
in support of BZA/CE as a safer therapeutic
alternative to HRT when breast and
endometrial outcomes are considered.
Furthermore, it may be better tolerated than
hormonal therapy alone, with fewer treatment-
limiting side effects. A summary of the overall
effects of BZA/CE versus HRT and SERMs is
provided in Table 1.
In reference to bone health outcomes,
current evidence is relatively encouraging. The
improvement in BMD with the approved
Table 1 Estrogen-related effects of the TSEC in comparison to raloxifene and HRT
Pharmacologic intervention TSEC Raloxifene HRT
Bone health : [29]b : [18, 50]a : [10, 51]b
Endometrial hyperplasia Neutral [49]b Varies [50, 52]a : [17]a
Breast cancer risk Unclear [40]b ; [15, 53]b : [4, 10]a
Vasomotor symptoms ; [31, 35]b : [18]b ; [54]a
Stroke risk Unclear [31]c Neutral [18, 50, 55]b : [4, 10]a
VTE risk Unclear [31]b : [18, 50]a : [4, 10]a
HRT hormone replacement therapy, SERM selective estrogen receptor modulators, TSEC tissue-selective estrogen complex,
VTE venous thromboembolism
a Grade 1A evidence
b Grade 2A evidence
c Grade 2C evidence
: denotes an increase in the relevant outcome
; denotes a decrease in the relevant outcome
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formulation of BZA/CE is, at the very least,
comparable to raloxifene. As these trials were
centered on evaluating efficacy with a
preventative goal, the gain in BMD alone
suggests it may be effective in delaying
progression to a high-risk fracture group.
However, more research is needed that
considers patient-important outcomes related
to osteoporosis, namely fracture prevention
data. Such data would help to clarify the role
of BZA/CE not only in the prevention, but also
in the treatment of osteoporosis. The role of
BZA/CE in the treatment algorithm for PMO as
compared to the other existing treatment
options still remains unclear.
The novelty of the medication means that
long-term data on safety are not yet available.
Perhaps, like HRT, the risk profile becomes
increasingly concerning with longer use and
older age. In this case it may be a great
alternative to HRT for vasomotor symptoms in
early postmenopausal women, but may not
provide lasting bone health improvements.
Without these outcomes, it is difficult to
predict what role BZA/CE will play in
osteoporosis prevention, especially when
considering the controversy among experts on
whether pharmacologic prevention is indicated.
In postmenopausal women with bothersome
menopause-related symptoms, BZA/CE appears
to be a better alternative to HRT, and may
provide an additional bone-protective benefit.
In the absence of vasomotor symptoms, there
may be a role for BZA/CE in postmenopausal
women at moderate risk for fracture in the
60–70 years age range, during which time
vertebral fractures are more prevalent;
however, after the age of 70 years, hip
fractures become a greater concern and the
drug’s clinical utility with respect to hip
fractures needs further clarification.
Finally, the evidence surrounding the
efficacy and safety of BZA/CE is based entirely
on preclinical studies and a single phase III trial
assessing multiple outcomes. Before any strong
conclusions can be drawn, the reproducibility
of these effects must be determined. Therefore,
while the current evidence suggests a possible
role for BZA/CE in the treatment algorithm for
osteoporosis, further evaluation is required to
confirm or refute the findings in this single
study.
This review article was based on previously
conducted studies and does not involve any
new studies of human or animal subjects
performed by any of the authors.
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